Context Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
CNTX$0.19-6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(23,238,998) | $(13,404,771) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Acquired in-process research and development charge | 6,500,000 | — |
| Share-based compensation expense | 937,322 | 682,831 |
| Depreciation and amortization expense | 11,334 | 8,120 |
| Reduction in the carrying amount of operating lease right-of-use asset | 70,244 | 52,737 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (470,017) | 34,972 |
| Accounts payable | 755,322 | 958,960 |
| Accrued expenses and other current liabilities | (2,946,188) | 855,651 |
| Operating lease liability | (68,130) | (52,061) |
| Net cash used in operating activities | (18,449,111) | (10,863,561) |
| Cash flows from investing activities: | ||
| Acquired in-process research and development | (4,500,000) | — |
| Purchase of property and equipment | (55,746) | (33,948) |
| Net cash used in investing activities | (4,555,746) | (33,948) |
| Cash flows from financing activities: | ||
| Payment of offering costs from the sale of common stock from ATM facility | — | (15,268) |
| Net cash used in financing activities | — | (15,268) |
| Net decrease in cash and cash equivalents | (23,004,857) | (10,912,777) |
| Cash and cash equivalents at beginning of period | 65,995,228 | 94,429,824 |
| Cash and cash equivalents at end of period | $42,990,371 | $83,517,047 |
| Supplemental disclosure of non-cash activities: | ||
| Right-of-use asset obtained in exchange for lease obligation | $201,058 | $— |
| Acquired in-process research and development charge included in accrued expenses | $2,000,000 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.